Ulcerative Colitis

Upadacitinib is now approved for ulcerative colitis, atopic dermatitis, and psoriatic arthritis.

The decision represents the first ever upadacitinib for a gastroenterological disease.

Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.

There was a 2.4-fold increase in cancer among patients with pediatric-onset inflammatory bowel disease.

Assessing fat free mass and reduced intake are particularly important in identifying malnutrition in patients with inflammatory bowel disease.

In data presented at ECCO 2022, investigators identified the optimal infliximab cut-off level was 4 μg/ml.

AHN is one of the few hospitals who have implemented this type of program to treat IBD complications.

There is no clinically meaningful differences in safety and efficacy between biologics and biosimilars.

Guselkumab is being studied as a treatment for both Crohn's disease and ulcerative colitis.

The data presented during ECCO 2022 involved IBD patients both in Hong Kong and the US.

There is concerns over missed early screenings for gastrointestinal cancers due to the COVID-19 pandemic.

The efficacy rates at weeks 12 and 52 were numerically lower in ileal only Crohn’s disease relative to colonic only and ileal-colonic.

A higher proportion of patients treated with mirikizumab achieved clinical remission at week 12 compared to placebo.

Brain development could be impaired due to iron deficiencies, leading to an increased risk of ADHD.

Some indicators of suboptimal response included discontinuation of anti-TNF therapy for patients with ulcerative colitis and IBD-related hospitalization for patients with Crohn’s disease.

Barnesiella was positively associated with the first principal component, and category fluency.

The treatment was comparable to darbepoetin alfa in treating patients with chronic kidney disease who were not undergoing dialysis.

Future studies should focus on subgroups of patients with Crohn’s disease treated with ustekinumab.

Less than 5% of patients with IBD treated with azathioprine had white blood count, eGFR, ALT, and neutrophil abnormalities.

The majority of drugs in development for IBD target inflammation.

About 30% of patients with ulcerative colitis do not adequately respond to anti-TNF therapy.

Bowel wall thickness and hyperemia in the neo-terminal ileum and bowel wall hyperemia at the ileocolic anastomosis were the only IUS parameters linked to endoscopic recurrence.

Balloon dilation is considered the gold standard in treating the complications associated with Crohn’s disease.

More than 70% of both groups met the primary efficacy outcomes.

The biggest theme identified was patients seeking peer-support and information about CPF symptoms, treatments, diet, experimental therapies, natural remedies, and patients’ apprehension regarding treatments.

Anti-TNF agents often cause various side effects, including inflammation.

Children of mothers with IBD are also more likely to be underdeveloped in height and weight compared to the control group.

Immunomodulators, incomplete vaccination, and non-mRNA vaccination were associated with a higher risk of adverse events for patients with IBD.

The endomina system can be affixed to various testing standard endoscopies for a bendable therapeutic channel.

The Prevalence of inflammatory bowel disease is highest in the Western world.